Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTIS: Tirofiban after Tenecteplase in Acute Ischemic Stroke
NCT05604638Phase 3Recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirofiban in ischemic stroke, sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: Functional independence (mRS 0-2) at 90 days. Started Apr 2024; status: recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05604638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604638.